Details:

Product information

Molecular formula: C28H37N3O3
Molecular weight: 463.61200
Exact quality: 463.28300
PSA: 67.59000
LogP: 4.79500
Density: 1.16g/cm3
Boiling point: 639.11oC at 760mmHg
Flash point: 340.3oC
Refractive index: 1.594
Steam pressure: 3.29E-17mmHg at 25°C

Bilastine is a non-sedating, long-acting antihistamine that can selectively antagonize peripheral H1 receptors without affinity for muscarinic receptors and low affinity for other receptors. It is suitable for the treatment of allergic rhinitis and urticaria, including adults and adolescents 12 years and older.
Bilastin tablets are developed by Spanish FAES FARMA company for the treatment of allergic rhinoconjunctivitis (seasonal and perennial) and urticaria. It was approved by the European Union in August 2010 for marketing in the United Kingdom, Spain, Germany, Denmark, Bulgaria , Sweden and other 10 European countries went public. It was approved by the FDA in April 2006 for clinical trials and is now in phase III clinical trials.

Certification of analysis

Function 

1. Allergic rhjinoconjunctivitis

The clinical efficacy of bilastine in allergic rhinitis (AR) and urticaria has been assessed in 10 clinical assays in which over 4,600 patients were involved. All of them compared bilastine with placebo and another second generation antihistamine with confirmed efficacy (active comparator).

2. Allergic rhinitis

The studies on SAR were double-blind, placebo-controlled, parallel-group involving male and female patients over 12 year of age with symptomatic disease at the beginning of the study. Nasal symptoms (sneezing, rhinorrhea, nasal itching and congestion) were assessed both before treatment and during treatment period on a daily basis. Non nasal symptoms (itchy eye, watery eye, itchy ear and palate) were also assessed according to a 0–3 scale, so that the Total Symptoms Score (TSS) and other related parameters could clearly reflect daily evolution of SAR in each patient and treatment group. Parameters such as quality of life and discomfort were also assessed, and in the same way the type and frequency of AE, tolerability and general safety of treatment were registered. In this SAR studies the daily oral administration during 14 days of bilastine proves to have the same efficacy as the administration of cetirizine and desloratadine.

Company Information

Hebei Mojin Biotechnology Co., Ltd, Our company is a professional in lead acetate, diphenyl ethylamine and other chemical raw materials and chemical reagents research and development production enterprises. Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.